Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Excess oxygen worsens lung inflammation in mice


Research performed at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has revealed that oxygen therapy aimed at helping mice with acute lung inflammation breathe paradoxically worsened their illness. The researchers say excess oxygen appears to thwart a natural process that limits lung tissue damage. They overcame this deleterious side effect, however, by adding an inhaled anti-inflammatory drug to the oxygen therapy.

"This research illustrates, in an animal model, a delicate balance between supplemental oxygen therapy and an innate tissue-preserving process that appears to operate best in low-oxygen conditions," says NIAID Director Anthony S. Fauci, M.D.

Michail Sitkovsky, Ph.D., senior author of the paper published this week in the journal PLoS Biology, believes the findings could have clinical implications. Supplemental oxygen is a life-saving therapy for patients with breathing problems, but it can harm the lungs if it is used for long periods. While the problem of oxygen-induced lung damage is well known, the biochemical processes leading to this damage have not been fully explained. Dr. Sitkovsky’s research reveals a possible mechanism behind this oxygen-induced damage and also provides evidence of a simple way to prevent it.

The current study extends research published in 2001 by Dr. Sitkovsky and colleagues into the role played by the molecule adenosine in regulating inflammation. Inflammatory chemicals produced by the immune system in response to infection or injury must eventually be switched off so that excessive tissue damage can be avoided. Dr. Sitkovsky and his colleagues have shown that inflammation leads to a drop in oxygen levels in the inflamed tissues. This, in turn, triggers the release of adenosine from surrounding cells. When adenosine binds to cell receptors in the inflamed region, it serves as a tissue-protecting stop signal, slowing the flood of damaging inflammatory molecules, the scientists found.

From these findings, they reasoned that oxygen therapy given to patients with acute lung inflammation might "short-circuit" this protective pathway by preventing oxygen levels from dropping enough to trigger the inflammation stop signal.

To explore this possibility in an animal model, Dr. Sitkovsky and his colleagues induced lung inflammation in three groups of mice. The first group of 15 mice did not receive any supplemental oxygen. While they sustained moderate lung damage, only two died. Another group of 15 mice with acute lung inflammation were treated with either 100 percent or 60 percent oxygen for 48 hours. These mice suffered very extensive lung damage, and 11 of 15 died. Finally, the scientists treated another 15 mice with acute lung inflammation with a combination of 100 percent oxygen and an adenosine-like drug to compensate for the oxygen-induced loss of natural adenosine. Only two mice in this group died, and exacerbation of lung inflammation by oxygen was prevented.

The investigators conclude that in this small animal model highly pure oxygen therapy without the addition of an adenosine substitute worsens pre-existing lung inflammation. "We suggest that these adenosine substitutes be evaluated for their possible usefulness in settings of acute lung inflammation due to infection or other causes, such as asthma or surgical trauma," says Dr. Sitkovsky.

Dr. Sitkovsky is now continuing his research at the newly established New England Inflammation and Tissue Protection Institute, a consortium at Northeastern University in Boston.

NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.

Anne A. Oplinger | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>